Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Tilray (TLRY), Immunovant (IMVT) and Palvella Therapeutics (PVLA)

Tipranks - Tipranks - Fri Apr 3, 7:14AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tilray (TLRY), Immunovant (IMVT) and Palvella Therapeutics (PVLA).

End of Quarter Sale - 50% Off TipRanks

Tilray (TLRY)

ATB Cormark Capital Markets analyst Frederico Gomes maintained a Hold rating on Tilray today and set a price target of $9.00. The company’s shares closed last Wednesday at $6.14.

According to TipRanks.com, Gomes is a 1-star analyst with an average return of -3.4% and a 52.5% success rate. Gomes covers the Healthcare sector, focusing on stocks such as Decibel Cannabis Company, Green Thumb Industries, and Organigram Global. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tilray with a $7.97 average price target, implying a 20.6% upside from current levels. In a report issued on March 22, TipRanks – Anthropic also upgraded the stock to Hold with a $6.00 price target.

See the top stocks recommended by analysts >>

Immunovant (IMVT)

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Immunovant today and set a price target of $49.00. The company’s shares closed last Wednesday at $25.10.

According to TipRanks.com, CFA is a 5-star analyst with an average return of 33.4% and a 64.5% success rate. CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Crinetics Pharmaceuticals, and Dianthus Therapeutics. ;'>

Currently, the analyst consensus on Immunovant is a Strong Buy with an average price target of $39.50, which is a 57.2% upside from current levels. In a report issued on March 19, TipRanks – Google also upgraded the stock to Buy with a $26.00 price target.

Palvella Therapeutics (PVLA)

In a report released today, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Palvella Therapeutics, with a price target of $227.00. The company’s shares closed last Wednesday at $120.38.

According to TipRanks.com, Ijem is a 5-star analyst with an average return of 24.2% and a 48.9% success rate. Ijem covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Vertex Pharmaceuticals. ;'>

Palvella Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $232.50, which is an 84.8% upside from current levels. In a report issued on March 19, Craig-Hallum also maintained a Buy rating on the stock.

Read More on TLRY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).